A LONG-TERM SURVEY OF MORPHINE IN CANCER PAIN PATIENTS

被引：109

作者：

SCHUG, SA

ZECH, D

GROND, S

JUNG, H

MEUSER, T

STOBBE, B

机构：

[1] Department of Pharmacology and Clinical Pharmacology, School of Medicine, University of Auckland, Auckland

[2] Department of Anesthesiology, University of Cologne, Cologne

来源：

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT | 1992年 / 7卷 / 05期

关键词：

CANCER PAIN; WHO GUIDELINES; MORPHINE; COANALGESICS; PHYSICAL DEPENDENCE; TOLERANCE; ADDICTION; SIDE EFFECTS;

D O I：

10.1016/0885-3924(92)90059-Q

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

We surveyed 550 cancer patients who experienced pain and were treated with morphine for a total of 22,525 treatment days. Sufficient pain relief was achieved during more than 80% of this time using an average oral morphine dose of 82.4 mg-significantly lower than other studies. The use of this low dose, which was possible due to the concomitant administration of nonopioids and specific coanalgesics in most patients, resulted in a low incidence of side effects. Constipation and nausea/vomiting were the most common of these side effects. Physical dependence posed no practical problem in discontinuation Of morphine treatment. Long-term opioid intake and development of tolerance did not appear to be linked; an increase in morphine dosage was most often explained by progression of the terminal disease. Addiction was a negligible problem, with only one observed case.

引用

页码：259 / 266

页数：8

共 42 条

[11]

Sjogren, Banning, Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids, Pain, 39, pp. 5-11, (1989)

[12]

Thirlwell, Sloan, Maroun, Et al., Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients, Cancer, 63, pp. 2275-2283, (1989)

[13]

Ventafridda, Tamburini, Caraceni, De Conno, Naldi, A validation study of the WHO method for cancer pain relief, Cancer, 59, pp. 851-856, (1987)

[14]

Schug, Merry, Acland, Treatment principles for the use of opioids in pain of nonmalignant origin, Drugs, 42, pp. 228-239, (1991)

[15]

Grond, Zech, Dahlmann, Schug, Stobbe, Lehmann, Intractable cancer pain as a reason for referral: analysis of pain etiology and previous drug treatment, Schmerz, 4, pp. 193-200, (1990)

[16]

Bruera, MacMillan, Hanson, MacDonald, The Edmonton staging system for cancer pain: preliminary report, Pain, 37, pp. 203-209, (1989)

[17]

Grond, Zech, Schug, Lynch, Lehmann, Validation of WHO guidelines for cancer pain relief during the last days and hours of life, J Pain Symptom Manage, 6, pp. 411-422, (1991)

[18]

Schug, Zech, Grond, A computerized documentation system for cancer pain management units, Comput Med, (1992)

[19]

Portenoy, Chronic opioid therapy in nonmalignant pain, Journal of Pain and Symptom Management, 5, pp. 46-62, (1990)

[20]

Arner, Meyerson, Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain, Pain, 33, pp. 11-23, (1988)

← 1 2 3 4 5 →